Abul Kalam Azad1, Xin Qiu2, Kevin Boyd1, Qin Kuang1, Marjan Emami1, Nicole Perera1, Prakruthi Palepu1, Devalben Patel1, Zhuo Chen1, Dangxiao Cheng1, Ronald Feld3, Natasha B Leighl3, Frances A Shepherd3, Ming-Sound Tsao4, Wei Xu2, Geoffrey Liu5, Sinead Cuffe3. 1. Ontario Cancer Institute, Princess Margaret Cancer Center/University Health Network, University of Toronto, Toronto, Ontario, Canada. 2. Department of Biostatistics, Princess Margaret Cancer Center/University Health Network, University of Toronto, Toronto, Ontario, Canada. 3. Division of Medical Oncology and Hematology, Princess Margaret Cancer Center/University Health Network, University of Toronto, Toronto, Ontario, Canada. 4. Department of Pathology, Princess Margaret Cancer Center/University Health Network, University of Toronto, Toronto, Ontario, Canada. 5. Ontario Cancer Institute, Princess Margaret Cancer Center/University Health Network, University of Toronto, Toronto, Ontario, Canada; Division of Medical Oncology and Hematology, Princess Margaret Cancer Center/University Health Network, University of Toronto, Toronto, Ontario, Canada; Division of Epidemiology, Dalla Lana School of Public Health, Toronto, Ontario, Canada. Electronic address: geoffrey.liu@uhn.on.ca.
Abstract
INTRODUCTION: Lung cancer is a leading cause of cancer-related mortality in North America. In addition to tobacco smoking, inherited genetic factors can also influence the development of lung cancer. These genetic factors may lead to biologically distinct subsets of cancers that have different outcomes. We evaluated whether genetic sequence variants (GSVs) associated with lung cancer risk are associated with overall survival (OS) and progression-free survival (PFS) in stage-III-IV non-small-cell lung cancer (NSCLC) patients. METHODS: A total of 20 candidate GSVs in 12 genes previously reported to be associated with lung cancer risk were genotyped in 564 patients with stage-III or IV NSCLC. Multivariate Cox proportional hazard models adjusted for potential clinical prognostic factors were generated for OS and PFS. RESULTS: After taking into account multiple comparisons, one GSV remained significant: rs4975616 on chromosome 5p15.33, located near the TERT-CLPTM1L gene. The adjusted hazard ratio (aHR) for OS was 0.75 (0.69-0.91), p = 0.002; for PFS aHR was 0.74 (0.62-0.89), p < 0.001 for each protective variant allele. Results were similar in both Stage III (OS: aHR = 0.70; PFS: aHR = 0.71) and Stage IV patients (OS: aHR = 0.81; PFS: aHR = 0.77). CONCLUSION: A GSV on 5p15.33 is not only a risk factor for lung cancer but may also be associated with survival in patients with late stage NSCLC. If validated, GSVs may define subsets of patients with different risk and prognosis of NSCLC.
INTRODUCTION:Lung cancer is a leading cause of cancer-related mortality in North America. In addition to tobacco smoking, inherited genetic factors can also influence the development of lung cancer. These genetic factors may lead to biologically distinct subsets of cancers that have different outcomes. We evaluated whether genetic sequence variants (GSVs) associated with lung cancer risk are associated with overall survival (OS) and progression-free survival (PFS) in stage-III-IV non-small-cell lung cancer (NSCLC) patients. METHODS: A total of 20 candidate GSVs in 12 genes previously reported to be associated with lung cancer risk were genotyped in 564 patients with stage-III or IV NSCLC. Multivariate Cox proportional hazard models adjusted for potential clinical prognostic factors were generated for OS and PFS. RESULTS: After taking into account multiple comparisons, one GSV remained significant: rs4975616 on chromosome 5p15.33, located near the TERT-CLPTM1L gene. The adjusted hazard ratio (aHR) for OS was 0.75 (0.69-0.91), p = 0.002; for PFS aHR was 0.74 (0.62-0.89), p < 0.001 for each protective variant allele. Results were similar in both Stage III (OS: aHR = 0.70; PFS: aHR = 0.71) and Stage IV patients (OS: aHR = 0.81; PFS: aHR = 0.77). CONCLUSION: A GSV on 5p15.33 is not only a risk factor for lung cancer but may also be associated with survival in patients with late stage NSCLC. If validated, GSVs may define subsets of patients with different risk and prognosis of NSCLC.
Authors: Linda Kachuri; Jens Helby; Stig Egil Bojesen; David C Christiani; Li Su; Xifeng Wu; Adonina Tardón; Guillermo Fernández-Tardón; John K Field; Michael P Davies; Chu Chen; Gary E Goodman; Frances A Shepherd; Natasha B Leighl; Ming S Tsao; Yonathan Brhane; M Catherine Brown; Kevin Boyd; Daniel Shepshelovich; Lei Sun; Christopher I Amos; Geoffrey Liu; Rayjean J Hung Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-07 Impact factor: 4.254
Authors: Z Chen; J Wang; Y Bai; S Wang; X Yin; J Xiang; X Li; M He; X Zhang; T Wu; P Xu; H Guo Journal: Cancer Gene Ther Date: 2016-12-16 Impact factor: 5.987
Authors: Hye Won Lee; Won-Jin Park; Jae-Ho Lee; Yu-Ran Heo; Tae In Park; Soo Young Park Journal: Onco Targets Ther Date: 2017-10-03 Impact factor: 4.147
Authors: Hang Li; Jun Che; Mian Jiang; Ming Cui; Guoxing Feng; Jiali Dong; Shuqin Zhang; Lu Lu; Weili Liu; Saijun Fan Journal: Cell Commun Signal Date: 2020-09-17 Impact factor: 5.712